Edition:
United Kingdom

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

1.75USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.75
Open
$1.73
Day's High
$1.79
Day's Low
$1.71
Volume
25,912
Avg. Vol
55,772
52-wk High
$5.99
52-wk Low
$1.66

Select another date:

Mon, Nov 13 2017

BRIEF-Cytrx announces new shareholder initiatives

* Cytrx Corporation provides business update and announces new shareholder initiatives

BRIEF-Cytrx reports strategic realignment of clinical development team

* Cytrx announces strategic realignment of clinical development team

BRIEF-Cytrx Corp announces reverse stock split

* Cytrx Corp- ‍1-for-6 reverse​ stock split will become effective as of commencement of trading on Wednesday, November 1, 2017 Source text for Eikon: Further company coverage:

BRIEF-CytRx Corp provides business update and highlights future plans

* CytRx Corp provides business update and highlights future plans

BRIEF-CytRx corp says Glass Lewis & Co recommends CytRx stockholders vote "for" proposed reverse stock split​

* CytRx Corp - proxy advisory firm Glass Lewis & Co. Recommends CytRx Corp stockholders vote "for" proposed reverse stock split​ Source text for Eikon: Further company coverage:

BRIEF-CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting

* CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting

BRIEF-Cytrx reports Q2 loss per share $0.10

* Cytrx corp - ‍cash, cash equivalents and short-term investments of $55.0 million as of june 30, 2017​ Source text for Eikon: Further company coverage:

BRIEF-Cytrx Corp announces Global Strategic License With Nantcell for Aldoxorubicin

* CytRX Corporation announces global strategic license with Nantcell Inc for Aldoxorubicin, an albumin mediated chemotherapeutic

Select another date: